These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23108520)

  • 1. New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
    Aalbers J
    Cardiovasc J Afr; 2012 Oct; 23(9):522. PubMed ID: 23108520
    [No Abstract]   [Full Text] [Related]  

  • 2. Place of dabigatran in contemporary pharmacotherapy.
    Gums JG
    Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
    [No Abstract]   [Full Text] [Related]  

  • 3. An anticoagulation option for nonvalvular atrial fibrillation.
    Shaheen MH; Das P; Koshy SK; Jha SK; Kabra R
    J Fam Pract; 2012 Jun; 61(6):E1-6. PubMed ID: 22670241
    [No Abstract]   [Full Text] [Related]  

  • 4. Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
    Heart Advis; 2011 Jan; 14(1):4. PubMed ID: 22973590
    [No Abstract]   [Full Text] [Related]  

  • 5. New drug offers warfarin alternative for atrial fibrillation. An immediate switch is right for some people, but not necessary for all.
    Harv Heart Lett; 2011 Feb; 21(6):5. PubMed ID: 21449127
    [No Abstract]   [Full Text] [Related]  

  • 6. Next generation anticoagulants may push warfarin to the wayside.
    Kirsch B
    Manag Care; 2011 Feb; 20(2):33-6. PubMed ID: 21428128
    [No Abstract]   [Full Text] [Related]  

  • 7. Warfarin or not.
    Oliver M
    J R Coll Physicians Edinb; 2010 Dec; 40(4):379; author reply 379-80. PubMed ID: 21132153
    [No Abstract]   [Full Text] [Related]  

  • 8. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New anticoagulants: better knowledge, better prescriptions].
    Boehlen F; de Moerloose P
    Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era for anticoagulation in atrial fibrillation.
    Mega JL
    N Engl J Med; 2011 Sep; 365(11):1052-4. PubMed ID: 21870977
    [No Abstract]   [Full Text] [Related]  

  • 11. Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
    Rahme RJ; Bernstein R; Batjer HH; Bendok BR
    Neurosurgery; 2011 Feb; 68(2):N16-7. PubMed ID: 21654569
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dabigatran: beyond the RE-LY study].
    García Alegría J
    Rev Clin Esp; 2012 Mar; 212 Suppl 2():1-3. PubMed ID: 23117715
    [No Abstract]   [Full Text] [Related]  

  • 13. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Tripodi A; Palareti G
    J Intern Med; 2012 Jun; 271(6):554-65. PubMed ID: 22443239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
    Ahrens I; Lip GY; Peter K
    Thromb Haemost; 2011 Apr; 105(4):574-8. PubMed ID: 21225102
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
    Hajhosseiny R; Sabir I; Lip GY
    Hosp Pract (1995); 2014 Oct; 42(4):153-62. PubMed ID: 25502139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Hunchuck JE; Lake JD
    Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
    [No Abstract]   [Full Text] [Related]  

  • 17. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
    Wann LS; Curtis AB; Ellenbogen KA; Estes NA; Ezekowitz MD; Jackman WM; January CT; Lowe JE; Page RL; Slotwiner DJ; Stevenson WG; Tracy CM; Fuster V; Rydén LE; Cannom DS; Crijns HJ; Curtis AB; Ellenbogen KA; Halperin JL; Kay GN; Le Heuzey JY; Lowe JE; Olsson SB; Prystowsky EN; Tamargo JL; Wann LS; Jacobs AK; Anderson JL; Albert N; Creager MA; Ettinger SM; Guyton RA; Halperin JL; Hochman JS; Kushner FG; Ohman EM; Stevenson WG; Yancy CW;
    Circulation; 2011 Mar; 123(10):1144-50. PubMed ID: 21321155
    [No Abstract]   [Full Text] [Related]  

  • 18. Dabigatran: will it change clinical practice?
    Wartak SA; Bartholomew JR
    Cleve Clin J Med; 2011 Oct; 78(10):657-64. PubMed ID: 21968472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
    Flaker G; Ezekowitz M; Yusuf S; Wallentin L; Noack H; Brueckmann M; Reilly P; Hohnloser SH; Connolly S
    J Am Coll Cardiol; 2012 Feb; 59(9):854-5. PubMed ID: 22361407
    [No Abstract]   [Full Text] [Related]  

  • 20. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.